A 42-year-old woman with bipolar disorder has been on olanzapine 15 mg/day for 14 months and is psychiatrically stable. She presents with a 6-month history of progressive weight gain (12 kg), fasting blood glucose 118 mg/dL, and triglycerides 280 mg/dL. Her BMI has increased from 24 to 29 kg/m². She is very concerned about her appearance and metabolic changes. What is the most appropriate next step in management?

Explanation

## Clinical Scenario Analysis The patient presents with **olanzapine-induced metabolic syndrome**: significant weight gain (12 kg over 6 months), impaired fasting glucose, hypertriglyceridemia, and elevated BMI. She is psychiatrically stable but experiencing distressing metabolic adverse effects. ## Antipsychotic-Induced Metabolic Syndrome Management Algorithm ```mermaid flowchart TD A[Antipsychotic-induced metabolic syndrome]:::outcome --> B{Psychiatric stability?}:::decision B -->|Unstable| C[Optimize current agent dose]:::action B -->|Stable| D{Metabolic severity?}:::decision D -->|Mild| E[Lifestyle + metformin]:::action D -->|Moderate-Severe| F{Switch feasible?}:::decision F -->|Yes| G[Switch to metabolically-neutral agent]:::action F -->|No| H[Reduce dose + adjunctive agent]:::action G --> I[Aripiprazole/Quetiapine/Ziprasidone]:::outcome H --> J[Topiramate/Metformin]:::outcome ``` ## Why Switch to Aripiprazole? **Key Point:** When an antipsychotic causes clinically significant metabolic syndrome in a psychiatrically stable patient, switching to a metabolically-neutral or metabolically-favorable agent is the preferred first-line intervention. ### Metabolic Profile Comparison | Antipsychotic | Weight Gain Risk | Glucose/Lipid Risk | Metabolic Neutral? | |---|---|---|---| | **Olanzapine** | Very High | Very High | No | | **Aripiprazole** | Very Low | Very Low | **Yes** | | **Quetiapine** | Moderate-High | Moderate-High | No | | **Ziprasidone** | Low | Low | Yes | | **Lurasidone** | Low | Low | Yes | **High-Yield:** Aripiprazole is a **partial D₂ agonist** with minimal affinity for histamine H₁ and muscarinic M₃ receptors—the mechanisms driving weight gain and metabolic dysfunction. It is the preferred switch agent for olanzapine-induced metabolic syndrome. ### Clinical Pearl The patient has been stable for 14 months on olanzapine, indicating good antipsychotic response. Switching to an equally efficacious but metabolically-favorable agent (aripiprazole) preserves psychiatric stability while addressing her distressing metabolic side effects and reducing long-term cardiovascular/diabetes risk. ## Why Other Options Are Suboptimal ### Option A: Continue Olanzapine + Metformin - Metformin provides *metabolic protection* but does not address the underlying cause (olanzapine's weight-promoting and glucose-dysregulating effects). - Patient will likely continue to gain weight and develop further metabolic derangement. - Not first-line when switching is feasible in a stable patient. ### Option C: Reduce Olanzapine + Add Topiramate - Dose reduction risks psychiatric relapse after 14 months of stability. - Topiramate is an adjunctive agent, not a primary solution; it adds medication burden. - Switching is superior to dose reduction + polypharmacy. ### Option D: Bariatric Surgery Referral - Premature and inappropriate as first-line intervention. - Bariatric surgery is reserved for severe, refractory obesity (BMI >40 or >35 with comorbidities) after conservative measures fail. - This patient's BMI is 29 (overweight, not obese); metabolic parameters are early-stage. [cite:Stahl's Essential Psychopharmacology 4e Ch 5; NICE Guidelines on Psychosis and Schizophrenia]